ROKAPAX vs. Artrya

Our diverse selection of products includes VNA, PACS systems, Radiology Information Systems (RIS), Diagnostic Viewers, and AI-enhanced Medical Diagnostic Support Solutions (MDSS) specifically designed for modalities such as MMG, CT chest imaging, ECG, and X-ray endoprosthesis imaging. With a robust user base of over 300,000 active individuals each month and 20,000 diagnostic devices flawlessly integrated with our PACS|VNA, we take pride in offering state-of-the-art technological solutions that aim to improve patient care significantly. We are keen to impart our knowledge in the field of healthcare digitalization, which is focused on elevating patient experiences through optimized diagnostic workflows. Our dedication extends to promoting the seamless adoption of our solutions to enhance the efficiency of professionals such as radiologists, oncologists, and cardiologists in their daily tasks. Leveraging 14 years of collaboration with 5,000 clinics, we have honed our essential skills to create a comprehensive and flexible platform that addresses the entire imaging workflow, free from vendor limitations. Furthermore, our AI-powered medical decision support systems are crafted to effectively prioritize cases with identified pathologies on a single interface, employing a red-yellow-green alert system to bolster clinical decision-making. This groundbreaking method guarantees that healthcare practitioners can concentrate on what is most important: providing outstanding care to their patients, thereby fostering a healthcare environment that is more responsive and patient-centered. Ultimately, our innovations not only streamline processes but also facilitate better health outcomes for all involved.

Artrya partners with clinics that focus on patients with chest pain to pioneer advanced AI-driven cardiovascular care models. This collaboration facilitates the integration of high-prognostic value plaque characteristics into the evaluation of coronary artery disease. In both emergency and primary care settings, swift assessments of chest pain patients become achievable. We foresee a future where heart attack occurrences within communities are drastically diminished. By leveraging AI insights from coronary computed tomography angiography (CCTA), healthcare providers can quickly categorize chest pain patients within minutes, based on the type and volume of arterial plaque identified. This innovative technology allows for the prompt detection of individuals with minimal or no coronary artery disease, ensuring that no concealed plaque characteristics are overlooked that could potentially lead to severe cardiac incidents in the future. Identifying early signs of a possible heart attack is of utmost importance. Furthermore, this method enables the effective identification of patients at risk who present with acute or atypical chest pain, guaranteeing they receive appropriate further evaluation and treatment. By adopting this proactive approach, not only are patient outcomes improved, but the overall health of the community is also enhanced, fostering a culture of preventive care. The ongoing commitment to integrating cutting-edge technology will continue to transform cardiovascular care for the better.